Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 11/25/2020 (updated 4/3/2024)
This Peer Integration Toolkit from Office of Addiction Services And Supports State of New York (OASAS) uses a stages of change framework to present guidance information. To effectively implement change, the organization will need to evaluate their current stage of change about the integration of peer services (pre-contemplation, contemplation, preparation, action or wellness).
Posted 5/22/2020 (updated 3/28/2024)
To identify Finnegan Neonatal Abstinence Scoring Tool tems independently associated with the decision to use pharmacologic therapy and to simplify the FNAST while minimizing loss of information for the treatment decision.
Posted 3/14/2023 (updated 3/27/2024)
Contingency management has empirical support but limited implementation. This report provides an overview of contingency management, barriers of implementation, and recommendation on how to overcome the challenges of implementation. Evidence-based treatment for people with stimulant use disorder is important as the U.S. has been experiencing an overdose crisis resulting in overdose deaths.
Posted 4/26/2022 (updated 3/27/2024)
Background: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programmes, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).